New obesity drug tirzepatide put to the test in paraguay clinic

NCT ID NCT07492563

Not yet recruiting Disease control Sponsor: LABORATORIOS INDUFAR Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test the safety and effectiveness of tirzepatide, a once-weekly injection, in 300 adults with obesity or overweight plus related health problems. Participants will receive increasing doses over 12 months while doctors track side effects, weight loss, and improvements in blood sugar and blood pressure. The goal is to see how well the drug works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide
What this could lead to: If successful, this study could confirm tirzepatide as a safe and effective option for long-term weight and diabetes management in real-world settings.
What could go wrong: This is an early-phase observational study, not a large confirmatory trial. Side effects like nausea or more serious events are possible, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT WITH COMORBIDITIES TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Endocrinology Unit, UNA, Py

Asunción, Paraguay

More trials for these conditions

Other studies related to the condition(s) this trial covers.